NAGE
New deal, bigger ambitions
Niagen Bioscience is taking another swing at turning its NAD+ story into something more than a good elevator pitch. The company announced a start-up agreement with Mass General Brigham investigators to begin detailed planning for what it says could become the largest and most comprehensive clinical trial of Niagen to date.
That’s a mouthful, sure. But the practical takeaway is simple: Niagen is trying to put more serious clinical muscle behind its healthy-aging thesis. And in biotech, a credible trial plan can matter almost as much as the data itself — because no one gets excited about “maybe someday” forever.
Why investors may care
If the study moves forward, it could give the company:
- more scientific validation around its patented nicotinamide riboside, or NR
- a larger platform to tell the market its NAD+ story
- a potential catalyst down the road if the trial design, enrollment, and results all land well
Of course, this is still the planning stage, so don’t expect a champagne pop just yet. A start-up agreement is not the same thing as a trial readout. It’s more like getting the blueprint before you break ground.
Big picture
For Niagen, the holy grail is turning “healthy aging” from buzzword soup into measurable clinical evidence. If this trial becomes the real deal, it could help the company graduate from science-project vibes to something closer to a bona fide biotech narrative. Big if, but investors love a good if.